PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Mayo Clinic develops AI capable of substantially improving dementia diagnoses
With the software's help, readers are up to three times more accurate and interpretations are nearly twice as fast.
FDA approves expanded use of PET imaging agent
The product's updated indications include quantification and long-term monitoring of amyloid plaques on imaging.
'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
Industry partnership set to advance research on theranostics
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.
SNMMI unveils its 2025 Image of the Year
The designation was awarded to a research team from China, who analyzed the efficacy of a novel radiotracer developed to target expression of the PD-L1 protein in suspected head and neck cancers.

FDA clears spinal-tap test that could challenge PET in Alzheimer’s diagnostics

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

CMS coverage decision for Alzheimer's drug, related PET scans sparks concern in imaging community

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

coronavirus COVID-19 vaccine vaccination

FDG PET/CT radiomics distinguishes between vaccine-related or metastatic breast cancer lymphadenopathy

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested.

Combination therapy that includes new radionuclide proves effective for metastatic prostate cancer

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

MRI/PET scans link brainstem atrophy to dementia symptoms

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.

New radiotracer that detects prostate cancer recurrence produces 'stunning' results

The research focused on a radiopharmaceutical that contains the isotope zirconium 89, which has a significantly longer half-life compared to gallium-68-labelled PSMA ligands.

PET scans spot brain abnormalities in long COVID patients

For 47% of patients with long COVID symptoms, brain PET scans identified mild to moderate or severe hypometabolic patterns.

FDA approves new radioligand therapy for PSMA positive metastatic prostate cancer

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression.

PET/CT

Mayo Clinic develops AI capable of substantially improving dementia diagnoses

FDA approves expanded use of PET imaging agent

'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer

Industry partnership set to advance research on theranostics

SNMMI unveils its 2025 Image of the Year